Robert Hardi

TL;DR: There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib or placebo twice daily.

TL;DR: Anti-IP-10 antibody, BMS-936557, is a potentially effective therapy for moderately-to-severely active UC and higher drug exposure correlated with increasing clinical response and histological improvement.

TL;DR: Among patients with quiescent UC and increased levels of FC, increasing the dose of mesalamine by 2.4 g/day reduced fecal concentrations of calprotectin to those associated with lower rates of relapse.

TL;DR: In patients with moderate‐to‐severely active CD who were refractory to or intolerant of immunosuppressants and/or anti‐TNF agents, ECP was well tolerated and induced clinical response (50%) and remission (25%) in patients.